Developing a treatment for Nipah Virus infection
Official title: Preclinical development of a Nipah Virus inhibitor
Funded at Collaborations Pharmaceuticals, INC. · NIH-10761349 · Data updated 2026-11-12
This study is looking at a potential new treatment for Nipah Virus using a medicine called pyronaridine, which has shown promise against other viruses, to see if it can help keep people safe and healthy if they get infected.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Collaborations Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Fuquay Varina, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $295,096 |
| NIH project number | 1R43AI174350-01A1 |
| Project ID | NIH-10761349 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at risk of Nipah Virus infection, particularly those in regions where the virus is prevalent.
✕Less likely to help
Patients who are not at risk of Nipah Virus infection or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on creating an effective antiviral treatment for Nipah Virus, a severe and often fatal disease transmitted from bats to humans. The team is investigating the antiviral properties of a compound called pyronaridine, which has shown promise against various viruses, including Ebola and SARS-CoV-2. The research involves testing the maximum tolerated dose and how the drug is processed in the body, aiming to establish a safe and effective treatment option for this dangerous virus. By understanding how pyronaridine works, the researchers hope to provide a new therapeutic option for patients affected by Nipah Virus.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment for Nipah Virus, potentially saving lives and reducing the severity of the disease.
How similar studies have gone: Previous research has shown success with antiviral compounds like pyronaridine against other viruses, indicating potential for this approach.
Where this research is happening
-
Collaborations Pharmaceuticals, INC.
Fuquay Varina, United States Active
Researchers
- Principal investigator: Ekins, Sean — Collaborations Pharmaceuticals, INC.
- Study coordinator: Ekins, Sean
Related research
Other NIH-funded projects on the same topics.
-
Long-term formulation for a combination HIV treatment
A new antiviral drug combination for people living with HIV is being developed to stay effective against resistant virus strains.
-
Using machine learning to find new treatments for poisoning and Alzheimer's disease
This research uses computer intelligence to discover new medicines that can help people affected by certain types of poisoning and conditions like Alzheimer's disease.
-
Developing a treatment for CLN1 Batten Disease using enzyme replacement therapy
This study is testing a new treatment for young children with CLN1 Batten Disease by delivering a special enzyme directly into their brains to help improve their brain function and overall quality of life.
-
Using machine learning to find new treatments for acetylcholinesterase inhibition
This study is looking for new ways to find compounds that can help block a brain enzyme linked to Alzheimer's disease, with the hope of discovering better treatments for patients.
-
Using machine learning to predict how drugs interact with human transporters
This study is looking at how different medications work with proteins in our bodies that help move substances in and out of cells, with the goal of creating safer drugs that have fewer side effects and work better for specific organs.
-
Analyzing and visualizing data for predicting toxic effects of new molecules
This study is looking at how computer models can help predict if new chemicals or drugs might be harmful, making it easier and safer to test them before they reach patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.